Xiaojiao Wang

21PUBLICATIONS
63CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersCancer cell biologyCancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (21)

|Aug 12, 2026
First-line PD-1/VEGF bispecific antibody plus chemotherapy in triple-negative breast cancer: a phase 2 trial.

|Jul 11, 2026
Axitinib promotes stemness and vasculogenic mimicry in triple-negative breast cancer by disrupting THBS1-CD47 axis-mediated endothelial-tumor cell communication.

|Oct 08, 2025
Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial.

Shanu Modi, William Jacot, Hiroji Iwata

|May 29, 2025
Circulating Tumor Cell Detection for Therapeutic and Prognostic Roles in Breast Cancer.

Saiying Ma, Xiaojia Wang, Peter Ping Lin

|May 09, 2025
Capivasertib plus fulvestrant in patients with HR-positive/HER2-negative advanced breast cancer: phase 3 CAPItello-291 study extended Chinese cohort.

Xichun Hu, Qingyuan Zhang, Tao Sun

|Apr 11, 2025
Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial.

Yongmei Yin, Ying Fan, Quchang Ouyang

Pageof 4

Frequent Collaborators

5 joint publications

Wenming Cao

4 joint publications

Shusen Wang

4 joint publications

Tao Sun

3 joint publications

Ziyan Yang